Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q86XP3

UPID:
DDX42_HUMAN

ALTERNATIVE NAMES:
DEAD box protein 42; RNA helicase-like protein; RNA helicase-related protein; SF3b DEAD box protein; Splicing factor 3B-associated 125 kDa protein

ALTERNATIVE UPACC:
Q86XP3; A6NML1; A8KA43; O75619; Q68G51; Q96BK1; Q96HR7; Q9Y3V8

BACKGROUND:
The ATP-dependent RNA helicase DDX42, known for its alternative names such as RNA helicase-like protein and SF3b DEAD box protein, is integral to RNA secondary structure unwinding. Its ability to displace single-strand RNA binding proteins through RNA duplex formation is essential for RNA metabolism. DDX42's function is intricately regulated by ATP and ADP, highlighting its role in both promoting and inhibiting RNA strand separation and annealing, respectively. Additionally, DDX42 interacts with TP53BP2, playing a pivotal role in cell survival by counteracting apoptosis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of ATP-dependent RNA helicase DDX42 holds significant promise for identifying new therapeutic avenues. Given its critical role in RNA metabolism and apoptosis regulation, DDX42 offers a valuable target for developing treatments that could impact a wide range of diseases characterized by abnormal RNA processing and cell death.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.